Pharma has a familiar playbook: take an old drug, reframe it as “new,” and price it like it’s never been treated before.
That’s the core tension behind the latest debate highlighted in DrugPatentWatch’s piece on how companies justify premium pricing fo…

Pharma has a new playbook—and it’s not always about new science.
In a world where “innovation” is the currency of premium pricing, drugmakers increasingly justify higher costs for repurposed medicines using a familiar narrative: same molecule, new valu…

Russia’s “third wheel” rule is supposed to be a footnote in the global drug supply chain. In practice, it’s a signal flare.
For years, observers have treated Russia’s API and drug manufacturing strategy as a reactive story—responding to sanctions, chas…

Europe’s divisional patent strategy is the quietest form of delay in Big Pharma’s playbook—and it’s getting harder to ignore.
Here’s the core issue: when a company can’t stop a patent challenge outright, it often doesn’t have to. It can instead keep th…

Pharma patent litigation used to be a $50M bet.
Now, it’s increasingly a $5M discipline.
That shift isn’t about “spending less.” It’s about spending smarter—earlier, with sharper evidence, and with a litigation strategy designed to survive both the c…

PBMs and rebates are no longer “back-office” topics. They’re board-level risk.
If you’re a pharma executive—commercial, strategy, finance, or legal—your next earnings cycle may hinge less on your pipeline slide and more on what happens after launch: fo…

🚨 Mark Cuban’s Cost-Plus Pricing Isn’t Just a Pricing Story—It’s a Patent-Playbook Story.
For years, Big Pharma has sold a simple narrative: innovation is expensive, patents are necessary, and high drug prices are the price of progress. But the re…

Should you file a provisional patent for your drug invention? The honest answer.
Most founders don’t lose sleep over whether to protect their IP. They lose sleep over how—and whether a “provisional” will buy them real leverage or just create a false se…

The “Patent Cliff” Isn’t a Cliff—It’s a Countdown. Start Building Supply-Chain Resilience Years Earlier.
There’s a familiar moment in pharma: the calendar flips, a patent expires, and suddenly the market looks like it’s on fire.
But the real story rare…

The 180-Day FDA Exclusivity Race Is Not a Sprint—It’s a Strategy War. Here’s the Playbook.
If you’re in generics, biosimilars, or branded pharma, you already know the headline: the first applicant to win the 180-day FDA exclusivity can capture outsized…